April 3, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Sara Mathew, Non-Executive Director of the Company, was appointed Director of State Street Corporation on March 29, 2018.
This disclosure is made pursuant to LR 9.6.14 of the UK Listing Rules.
Senior Assistant Company Secretary
For further information please contact:
|Christoph Brackmannemail@example.com||+41 795 432 359|
|Robert Coatesfirstname.lastname@example.org||+44 203 549 0874|
|Sun Kimemail@example.com||+1 617 588 8175|
|Katie Joycefirstname.lastname@example.org||+1 781 482 2779|
NOTES TO EDITORS
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.